{
  "abstract": "Objective: Assess the impact of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, on arthritis in patients with systemic lupus erythematosus (SLE) in a post-hoc analysis from the PAISLEY SLE study (NCT03252587).\n\nMethods: PAISLEY SLE was a 48-week, global, double-blind, placebo-controlled, phase II study evaluating deucravacitinib (3 mg two times per day), 6 mg two times per day and 12 mg one time per day in SLE. Patients with ≥6 swollen, tender or active (swollen plus tender) joints and those with any joint involvement at baseline were evaluated from weeks 4 to 48. Arthritis efficacy was assessed by 100% reduction (JC-100) or ≥50% reduction (JC-50) from baseline in joint count using non-responder imputation. ORs were calculated using logistic regression. Proportions of patients demonstrating musculoskeletal involvement, as assessed by British Isles Lupus Assessment Group 2004 (BILAG-2004) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) domain scores, were also evaluated.\n\nResults: More patients achieved JC-100 with deucravacitinib versus placebo whether they had ≥1 or ≥6 tender or active joints at baseline. At week 48, JC-100 active joint responses in patients with ≥6 joints involved were deucravacitinib 3 mg two times per day (n=38/63), 60.3%; 6 mg two times per day (n=26/65), 40.0%; 12 mg one time per day (n=28/62), 45.2%; and placebo (n=20/64), 31.3%. At week 48, ORs for JC-100 for swollen, tender or active joints with deucravacitinib 3 mg two times per day versus placebo were 3.4, 2.0 and 3.3, respectively. Comparable responses and ORs were seen with achievement of JC-50 for swollen, tender or active joints at all deucravacitinib doses. More patients receiving deucravacitinib versus placebo had musculoskeletal score improvements by both BILAG-2004 and SLEDAI-2K at week 48.\n\nConclusion: Deucravacitinib was associated with improvements in arthritis in patients in the phase II PAISLEY SLE study. Results will be further evaluated in ongoing phase III studies.",
  "abstract_shown": true,
  "affiliations": [
    "Rheumatology, MedPharm Consulting Inc, Bethesda, Maryland, USA",
    "Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York, USA",
    "Rheumatology, Northwell Health, Great Neck, New York, USA",
    "Department of Medicine, The University of Queensland, Brisbane, Queensland, Australia",
    "Charité University Hospital Berlin, Berlin, Germany",
    "Bristol Myers Squibb, Princeton, New Jersey, USA",
    "Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA",
    "The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Marilyn Pike",
      "orcid": "0009-0007-7760-5293"
    },
    {
      "affs": [
        1
      ],
      "name": "Amit Saxena"
    },
    {
      "affs": [
        2
      ],
      "name": "Richard A Furie",
      "orcid": "0000-0001-6712-1585"
    },
    {
      "affs": [
        3
      ],
      "name": "Peter Nash"
    },
    {
      "affs": [
        4
      ],
      "name": "Thomas Dörner",
      "orcid": "0000-0002-6478-7725"
    },
    {
      "affs": [
        5
      ],
      "name": "Coburn Hobar"
    },
    {
      "affs": [
        5
      ],
      "name": "Samantha Pomponi"
    },
    {
      "affs": [
        5
      ],
      "name": "Ying-Ming Jou"
    },
    {
      "affs": [
        5
      ],
      "name": "Subhashis Banerjee"
    },
    {
      "affs": [
        5
      ],
      "name": "Thomas Wegman"
    },
    {
      "affs": [
        6,
        7
      ],
      "name": "Joan T Merrill"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/611ghw9kwksa1.bib",
  "cited_by": 0,
  "doi": "10.1136/lupus-2026-002198",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13723908/",
  "id": "611ghw9kwksa1",
  "issns": [
    "2053-8790"
  ],
  "landing_url": "https://doi.org/10.1136/lupus-2026-002198",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "1506"
    ],
    [
      "heading",
      "2250"
    ],
    [
      "heading",
      "Clinical Trials and Drug Discovery"
    ],
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2745|Systemic Lupus Erythematosus Research"
    ]
  ],
  "openalex": "W7224362419",
  "pdf_url": "https://lupus.bmj.com/content/13/2/e002198.full.pdf",
  "pmcid": "PMC13723908",
  "pmid": "42957325",
  "published": "2026-10-29",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/611ghw9kwksa1.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:22:27Z",
      "native_id": "PMC13723908",
      "source": "pmc",
      "url": "https://doi.org/10.1136/lupus-2026-002198"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2745|Systemic Lupus Erythematosus Research",
      "subfield": "general"
    }
  ],
  "title": "Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study",
  "title_text": "Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-05T12:20:38Z",
  "url": "https://research.draconitic.com/paper/611ghw9kwksa1",
  "venue": "Lupus Science & Medicine",
  "versions": []
}